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Commentary
Studying the health impacts of environmental 
exposures on children is assuming increas-
ing importance. There is a general recogni-
tion that children are more vulnerable to such 
exposures by virtue of the higher doses they 
receive and their increased susceptibility (Sly 
and Flack 2008). Children’s increased suscep-
tibility is a consequence of the higher exposure 
and uptake, relative immaturity of meta  bolic 
and excretory pathways, and incomplete 
development of target organs [World Health 
Organization (WHO) 2006]. Children with 
the null mutation of glutathione S-transferase 
enzymes are at increased risk of asthma when 
exposed to traffic-related pollutants (Romieu 
et al. 2006), and children with a specific muta-
tion in paraoxonase-1 are more susceptible to 
the adverse effects of exposure to pesticides 
(Holland et al. 2006). However, the fact that 
an individual child may be at increased risk 
from adverse effects from environmental expo-
sures does not guarantee that the individual 
child will develop the adverse effect.
The range of environmental exposures 
affecting children’s health is expanding with 
increasing urbanization, especially in devel-
oping and emerging countries. Children liv-
ing in mega-cities and heavily industrialized 
cities are exposed to levels of air pollutants 
far higher than those of their counterparts 
in many developed countries (Mucha et al. 
2006; Romieu et al. 2002). Children are likely 
to participate in recycling activities involving 
recovering saleable but toxic components such 
as lead from batteries and components from 
discarded electronic equipment and computers 
(Holdren et al. 2008). The rapid introduction 
of new chemicals in many countries, espe-
cially where the health effects have not been 
fully evaluated, are likely to pose a problem 
for children (e.g., polybrominated flame retar-
dants used in children’s sleepwear), especially 
in developed countries (Holdren et al. 2008).  
Assessing exposures in children is more 
difficult than it is in adults (Needham and 
Sexton 2000). One approach to exposure 
assessment in children is to measure biomark-
ers of exposure and biomarkers of the effects 
of that exposure. A biomarker of exposure is 
a xenobiotic substance or its metabolite that 
is measured in the body and can be related 
to an environmental exposure; examples 
include measuring cotinine in urine or blood 
to give an indication of exposure to nicotine 
in tobacco smoke and measuring benzene 
metabolites in urine to give an indication to 
exposure to traffic-related pollution. Where a 
metabolite is measured, the child’s ability to 
metabolize the pollutant as well as the expo-
sure must be considered. A biomarker of effect 
measures direct or indirect consequences of 
the environmental exposure and incorporates 
the child’s ability to defend against the expo-
sure—for example, exposure to traffic-related 
pollutants results in the generation of reac-
tive oxygen species in the lungs and oxidative 
stress if the antioxidant defenses in the lungs 
are overwhelmed (WHO 2001). Oxidative 
stress in the lungs can result in tissue dam-
age from diverse mechanisms, including lipid 
peroxidation, protein halogenation, and DNA 
oxidation. By-products of these processes [e.g., 
8-isoprostone and malondialdehyde (Romieu 
et al. 2008) from lipid peroxidation, 3-chloro-
tyrosine from protein halogenation (Harwood 
et al. 2006), and 8-oxodeoxyguanosine from 
DNA oxidation (Cooke et al. 2006)] can 
be measured in various body compartments 
including the lungs (sputum, bronchoalveolar 
lavage), blood, and urine. Clinical effects on 
the child [e.g., lower lung function in children 
exposed to tobacco smoke, especially dur-
ing pregnancy (Stick et al. 1996; Vork et al. 
2007), or exposed to traffic-related pollution 
(Gauderman et al. 2004), and delayed neuro-
development in children exposed to neuro-
toxicants (Sly and Flack 2008)] can also be 
considered to be biomarkers of effect. 
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In some circumstances it is also possible 
to measure biomarkers of susceptibility to 
environmental exposures. This concept is 
best understood in the field of cancer, where 
specific chromosomal markers are related to 
disease susceptibility and prognosis (Duncan 
2004; Malkin 2004), but does occur in non-
cancer fields, for example, red cell glucose-6-
phosphate dehydrogenase deficiency. 
Biomarkers can be used in intervention 
studies to determine the efficacy of environ-
mental interventions. Biomass fuel burning is 
an enormous problem globally, and fuels used 
for domestic cooking or heating emit a com-
plex mixture of organic compounds and gasses 
that can include carbon monoxide, oxides of 
nitrogen and sulfur, aldehydes, poly  aromatic 
hydrocarbons (PAHs), volatile organic com-
pounds, chlorinated dioxins, and particulate 
matter when burned. Torres-Dorsal et al. 
(2008) studied the efficacy of improved stoves 
and housing on exposure of children to the 
emissions from biomass fuel combustion. 
They demonstrated a reduction of exposure 
as the serum levels of 1-hydroxypyrene (bio-
marker of PAH exposure) and carboxyhemo-
globin (biomarker of CO exposure) declined 
and a reduction of effects via a reduction in 
DNA damaged, assessed using a comet assay 
(Torres-Dorsal et al. 2008).
Ethical Aspects of Research 
Involving Children
The study of biomarkers in children raises 
a number of special ethical considerations 
related to the collection and storage of speci-
mens, consent, and how to convey informa-
tion about risk, especially where the level of 
scientific knowledge is inadequate to quantify 
that risk (Eskenazi et al. 2005). Many of these 
issues are similar to those involving adults 
(Caulfield et al. 2007; Evans and Meslin 2006; 
Helft et al. 2007; Malkin 2004), but other 
issues may be unique to children (Neidich 
et al. 2008). In this commentary we concen-
trate on issues specifically related to children 
rather than general issues. 
Pediatric biomarker research is especially 
worthy of special ethical scrutiny, because 
it invokes issues arising in pediatric research 
generally coupled with those of environmen-
tal health—biobanking and genetics research 
more specifically. Moreover, when these types 
of studies are carried out in economically 
developing countries, further ethical issues 
emerge. Before turning to the particular issues 
in pediatric biomarker studies, we first discuss 
the general ethical issues in pediatric research.
The ethics of research involving children 
has a long and profound history including 
important debates in the early 1960s that 
made compelling arguments for and against 
(McCormick 1976; Ramsey 1976). With the 
revelations of unethical research involving 
medicines in pregnant women, children, and 
fetuses in the 1960s (Beecher 1966), land-
mark legislation was passed in 1974 by the 
U.S. Congress which, among other actions, 
established the National Commission for the 
Protection of Human Subjects of Biomedical 
and Behavioral Research (1979). Several 
commission reports, including Research on 
the Fetus (National Commission for the 
Protection of Human Subjects of Biomedical 
and Behavioral Research 1975), Research 
Involving Children (National Commission 
for the Protection of Human Subjects of 
Biomedical and Behavioral Research 1977), 
and the Belmont Report (National Commission 
for the Protection of Human Subjects of 
Biomedical and Behavioral Research 1979), 
provided the ethical foundations for what 
would become the U.S. regulatory mecha-
nism to protect human subjects from harm, 
including the Common Rule (45 CFR 46, 
Subpart A; Department of Health and Human 
Services 2005), the relevant FDA regulations 
(21 CFR 50/56; FDA 1998), and additional 
provisions for the protection of other vulner-
able subjects including children (45 CFR 
46, Subpart D; Department of Health and 
Human Services 2005). 
Statements on the ethical conduct of 
research issued by various national and 
professional bodies generally include a sec-
tion outlining the special requirements for 
including children in research [Canadian 
Institutes for Health Research 2007; Council 
for International Organizations of Medical 
Sciences (CIOMS) 1993; Meslin and Johnson 
2008; National Health and Medical Research 
Council Australia 2007; National Institutes 
of Health 1998; World Medical Association 
2008]. Common to all of these guidelines are 
three general protections: 
•	Sound	justification—the	presumption	that	
children should not be included in research 
unless there is a compelling reason to do so. 
This has the potential to exclude children 
from important research. In an attempt 
to address this issue, a major shift in U.S. 
regulatory policy occurred in 1993. Rather 
than excluding women and children from 
research, the National Institutes of Health 
(NIH) made clear its commitment to 
requiring that women be included in trials 
unless there was a reason not to in the 1993 
NIH Reauthorization Act (NIH 1993). 
•	Informed consent—the basis for this assess-
ment is sometimes found in the bioethical 
principle of respect for persons described in 
the Belmont Report (National Commission 
for the Protection of Human Subjects of 
Biomedical and Behavioral Research 1979) 
or respect for autonomy (Beauchamp and 
Childress 2005). Both principles under-
stand that only adults are presumed to have 
the capacity to act autonomously, whereas 
children are not presumed to have this 
capacity. In general, consent is given on 
their behalf by parents or legal guardians, 
usually supplemented by the positive affir-
mation (or assent) of the child where pos-
sible (De Lourdes Levy et al. 2003). 
•	Prior ethics review.
An expanded discussion of these princi-
ples and the impact on research in children 
can be found in the Supplemental Material 
(doi:10.1289/ehp.0800480.S1).
Local versus global ethical standards. 
Common to most guidelines that address 
research involving children is a recognition 
that certain bioethical principles ought to 
guide decision making. Some of these, such 
as respect for persons, beneficence, and justice, 
have provided the moral foundation for the 
protections now commonly adopted by ethics 
review committees in the United States and 
elsewhere. Although these principles reflect 
the high value Western societies place on indi-
vidual autonomy, it is important to remember 
that this is not the only way in which humans 
interact and responsibilities are conceptualized 
in various non-Western societies and in some 
indigenous societies within Western countries. 
These factors also play a role in determining 
the ethical acceptability of conducting research 
on children in those communities. However, 
other principles have been suggested and 
defended, including solidarity and community 
participation (CIOMS 1993; Emanuel and 
Weijer 2005; Needham and Sexton 2000).
The national and international statements 
governing research in economically developed 
countries generally do not recognize the impor-
tance of local community values, either within 
a country or between countries. Research-
funding agencies generally require researchers 
to obtain ethical approval for the research to be 
conducted in the jurisdiction from which the 
funding has been obtained, regardless of where 
the research is to be conducted. Problems 
may arise when funding is obtained in an eco-
nomically developed country for research to 
be conducted in an economically developing 
country. This issue has been highlighted in 
the area of clinical trials (Sewankambo and 
Ijsselmuiden 2008; Shaffer et al. 2006; Shapiro 
and Meslin 2001), but applies to other area of 
research as well (Andanda 2008; Angell 1997; 
Anonymous 2007; Sharp and Zigas 2002). 
Clearly, researchers should take the local cul-
tural issues into consideration (Meslin 2009; 
Widdows 2007), and ethics review boards in 
economically developed counties should give 
preference to the local cultural values and dif-
ferences in laws, for example, laws governing 
privacy of participants and security of data 
(Sidle et al. 2006). 
There is a particular problem regarding 
obtaining informed consent when collabora-
tions are established in communities where the Ethics of biomarker research in children
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cultural practice is that consent is provided by 
the leaders of the community, not by individu-
als. This practice is obviously contrary to the 
basic assumptions behind our Western concept 
of informed consent. However, to ignore the 
culture of a community is both inappropriate 
and will almost certainly doom any prospect 
of collaboration. The best practice that bridges 
cultures is for the investigators to first obtain 
approval for the study from the community 
leaders or whoever is the traditional gatekeeper 
for the community. If that is successful, then 
the investigators can approach the individuals 
to obtain their agreement to participate fol-
lowing usual procedures. However, even if this 
sequence is followed, there are justifiable con-
cerns: Often the community leaders will basi-
cally order the members to participate, and the 
individuals feel that they have no alternative 
but to agree with that decision. Although this 
is not what is meant by informed consent and 
may not easily pass institutional ethics review 
boards, the alternative is that no studies can be 
done with these communities. This is equally 
unacceptable and discriminatory. 
Ethical Issues in Biomarker 
Research in Children
The study of biomarkers in children raises 
several ethical issues. Many of these arise 
in research involving children generally, as 
described above; others are more particularly 
related to the collection and storage of speci-
mens, consent, and how to convey informa-
tion about risk, especially where the level of 
scientific knowledge is inadequate to quantify 
that risk (Eskenazi et al. 2005). Many of these 
issues are similar to those involving adults 
(Caulfield et al. 2007; Evans and Meslin 
2006; Helft et al. 2007), but other issues may 
be unique to children (Neidich et al. 2008). 
We highlight two of these issues. 
Community expectations. Research using 
biomarkers is carried out to learn about what 
a particular biomarker can tell the researchers 
about environmental exposures, susceptibil-
ity, or risks for adverse health outcomes from 
those exposures. Thus, such research is gen-
erally undertaken in exposed communities, 
which may raise expectations within the com-
munity that the study will per se improve the 
situation in the community (Eskenazi et al. 
2005). However, the reality is that, in many 
cases, the risks are poorly understood and the 
primary purpose of conducting the study is to 
clarify the associations between exposures and 
health consequences and the role of biomark-
ers in understanding these associations. As 
pointed out by Eskenazi et al. (2005), under-
standing the community expectations and 
developing a communication strategy before 
starting the research is an important part of 
biomarker research. These issues are high-
lighted in two case reports outlining studies 
in children exposed to pesticides [Children’s 
Environmental Exposure Research Study 
(CHEERS)] or lead (Kennedy Krieger), which 
are included in the Supplemental Material 
(doi:10.1289/ehp.0800480.S1). These cases 
provide valuable lessons for conducting envi-
ronmental health research in a community.
What can a community reasonably expect 
from participating in biomarker research? 
There is no simple answer to this ques-
tion, because community expectations from 
research often vary widely. Thiessen et al. 
(2007) undertook an assessment of what 
individuals in a low-income community in 
Uganda perceived as benefits and harms of 
population-based human immunodeficiency 
virus/sexually transmitted disease (HIV/STD) 
research in their community. Those who par-
ticipated and those who declined participa-
tion equally believed that there were benefits 
to participation. Those who had declined to 
participate, frequently because they believed 
that they were being harmed, believed that 
the research would benefit the local economy, 
improve health worker knowledge about 
HIV/STD, and improve health of local resi-
dents in the future (Thiessen et al. 2007). 
Improved knowledge about the health risks 
from environmental exposures can be of ben-
efit to communities in which that research 
is undertaken. However, it is important to 
clearly communicate to communities what 
they can and cannot expect from the research. 
Models for engaging communities on this 
topic exist, one of which is referred to as a 
prior agreement, in which communities and 
researchers negotiate in advance of a study 
what benefits may be expected or provided at 
the end of the study (Page 2004).
Return of research results. Although there 
may be a general expectation that research 
results will be communicated to the study par-
ticipants and to the community, both practice 
and ethical guidance vary widely. Some argue 
that only under exceptionally rare circum-
stances should research results be returned to 
study participants—specifically, those instances 
in which a known harm can be avoided by 
referring a person to a physician and where 
the test result is valid (Wolf and Lo 2004). 
This argument is especially germane to genetic 
information when the results were obtained 
from a research laboratory and not a clinical 
genetics facility whose focus is on providing 
diagnostic quality data to patients. In the lat-
ter case, providing results of clinical tests that 
have a direct bearing on the health of an indi-
vidual is relatively straightforward, and few 
would argue against this approach. However, 
the further the data stray from having a direct 
effect on the health of the individual, the more 
opinion varies. Such issues have recently been 
highlighted in discussions of predictive genetic 
testing in young people (Duncan 2004; Malkin 
2004; Quaid et al. 2004). Duncan (2004) 
recently reviewed the ethics of such predictive 
genetic testing in children and reported that 
the default position in guidelines published 
by the international Huntington Association 
and the Clinical Genetics Society is to refuse 
testing for young people < 18 years of age. This 
opinion is based on the view that the psycho-
social harm involved in testing outweighs any 
benefits in the absence of preventative treat-
ments. These arguments could also be applied 
to much biomarker research, especially in chil-
dren. However, this would result in children 
being excluded from studies on environmental 
exposure where biomarkers are measured.
Much current biomarker research is con-
ducted to understand what, if any, role bio-
markers can have in understanding the health 
consequences of environmental exposures. In 
these cases, almost by definition, there is a lack 
of knowledge about how the level of or the 
presence of a particular biomarker translates 
into disease risk for an individual, and one 
could well argue that communicating infor-
mation that the researcher cannot understand 
to research participants and communities is an 
abrogation of the researcher’s responsibility. 
To tell a mother that her child has a detectable 
level of a certain biomarker without also being 
able to tell her what that means in terms of 
disease risk may do more harm than good. 
The opposing point of view, that partici-
pants have the right to know, would lead 
researchers to provide results even in the face 
of uncertainty of their significance. Needham 
and Sexton (2000) express this in terms of 
an explicit or implicit social contract between 
the researchers and the participants that 
stipulates that the researchers will interpret 
the health significance of measured exposure 
levels. This would also extend to biomarkers. 
Thus, where the data cannot be interpreted 
in terms of health significance, should they be 
  communicated to participants? 
This dilemma of providing results is 
illustrated in the Center for the Health 
Assessment of Mothers and Children of 
Salinas (CHAMACOS) study, a longitudinal 
birth cohort study of pesticide exposure and 
health consequences to children from primar-
ily poor Latino farmworker families living in 
California (CHAMACOS 2009). This study 
is a community-based participatory research 
project that receives advice from a commu-
nity advisory board on research issues. As 
part of the exposure assessment, urine from 
women and children was analyzed for pesti-
cide metabolites. When the CHAMACOS 
study began in 1999, there were no reference 
data, and the health effects associated with 
these levels was unknown. Consequently, the 
researchers, in consultation with the commu-
nity advisory group, stated clearly in the con-
sent forms that no individual results would be Sly et al.
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disclosed. However, in 2003, U.S. National 
Health Survey data became available, allow-
ing for the levels in the CHAMACOS study 
participants to be compared with a national 
reference. Members of the study’s community 
advisory board felt strongly that the results 
should then be disclosed to participants, 
although the health consequences were still 
unknown. With ethics review board approval, 
consent forms were changed, and results 
were then provided in person to parents who 
requested them. No adverse consequences of 
this change in policy have been noted. 
Conflicting ethical obligations. Community-
based research, especially when conducted 
in vulnerable populations, has the risk of 
creating conflicting ethical obligations for 
researchers. For example, protecting against 
unauthorized access to confidential information 
about research participants is a key focus of eth-
ics review boards, researchers, and research par-
ticipants. However, legal obligations, including 
mandatory reporting of child abuse and ille-
gal activities, can put researchers in a difficult 
position if such activities are revealed during 
the research. In the United States, the new 
Genetic Information and Nondiscrimination 
Act (2008) provides protections, and certifi-
cates of confidentiality afford specific protec-
tions against certain compelled disclosures, but 
neither has been tested in cases of pediatric 
biomarker research. Participants might expect 
that researchers will not reveal details of private 
conversations between children and researchers 
to the child’s parents without the express con-
sent of the child, or about children or family 
members to authorities. What do researchers 
do about information that children are being 
abused, engaging in risky sexual practices, or 
abusing substances if these are revealed dur-
ing a confidential interview or observation? 
One option is to establish an external reference 
group that will consider the appropriate action 
to be taken if such disclosures are made. If the 
existence and purpose of the reference group is 
made known to the research participants and 
their parents before their consent to partici-
pate, the ethical dilemmas can be reduced. In 
the CHAMACOS study, the consent explic-
itly states that “if we see or hear something 
that would endanger you, your child, or oth-
ers, we may discuss it with you, if possible, or 
seek help. If we learn that your child may be 
harmed, we may have to report this to Child 
Protective Services.” In this way, it is clearly 
stated that the child’s safety is paramount and 
that in cases where the child is considered to be 
at risk, confidentiality will be broken to protect 
the child.
Informed  consent.  The  principle 
under  lying informed consent—personal 
  autonomy—presumes that individuals will 
be given sufficient information to make an 
informed choice about their participation 
in research. However, we wonder whether 
informed consent can be obtained from 
research participants in biomarker research 
if the researchers themselves do not fully 
understand the relationship between envi-
ronmental exposures, biomarkers, and health 
consequence. A similar problem arises for 
biobanks when researchers ask potential par-
ticipants to donate DNA or tissue that may 
not be used for many years in the future and 
for which no specific research protocol has 
been designed. As with one-time consent for 
biobanks (Caulfield et al. 2007), the challenge 
is whether research participants have sufficient 
information to decide. We think that if the 
research proposal adequately discloses the lack 
of the researcher’s knowledge and describes the 
research purpose to the best of the researcher’s 
ability, subjects and communities can make 
an appropriate decision about participation 
(Schulte et al. 1997). 
The issue of competent minors also comes 
into determining who is able to give consent 
for research procedures. In some jurisdictions, 
including Australia, legally recognized consent 
to participate in research can be given only by 
individuals ≥ 18 years of age. Parents or legal 
guardians are obliged to give consent for chil-
dren under this age to participate. However, 
legal minors can consent to the provision 
or withholding of medical treatments if, in 
the view of the treating physician, they are 
competent to make such a decision. Where 
research involves the provision of medical 
treatment, the situation is less clear (Dixon-
Woods et al. 2006). 
In the absence of legal consent from chil-
dren, the practice adopted in most countries 
is to obtain assent from the child to participate 
in the research provided a parent or guardian 
provides consent. The assent of a child can-
not override a parental decision to withhold 
consent, but neither should the consent of a 
parent or guardian override a child’s decision 
not to assent to the research (De Lourdes Levy 
et al. 2003). Researchers should respect the 
wishes of the child about not participating in 
research. The issue of when a child is com-
petent to provide assent is not a simple one. 
A reasonable practice is to provide children 
with simple information sheets written in age-
appropriate language that sets out exactly what 
will be expected of them and what will hap-
pen to them in the research. This information 
should also explain in simple and explicit lan-
guage that the child has the right to change his 
or her mind at any time and withdraw from 
the research without fear of consequence.
Another issue frequently faced in longitu-
dinal studies, especially those in which biologi-
cal samples or biomarkers have been collected 
and stored, is obtaining consent from partici-
pants once they gain the age of legal majority 
(18 years of age in most jurisdictions). The 
generally held view is that researchers must 
contact participants where consent was given 
by a parent or guardian and obtain consent for 
the continued use of data and biological speci-
mens. Difficulty in contacting participants is 
not usually an acceptable excuse for not doing 
so. Indeed, U.S. research regulations expressly 
prohibit the inconvenience of obtaining con-
sent as an acceptable justification for not try-
ing. A more rigid criterion, impracticability, 
is used, which refers to a level of difficulty that 
would make it virtually impossible to carry 
out the study. That is, if obtaining consent, 
including recontacting those who gave diag-
nostic samples for use in research, makes it 
extremely difficult to carry out the study, then 
ethics committees are permitted to waive the 
consent requirement. 
The legal issues involved in determining 
ownership and intellectual property rights 
over stored biological samples are complex 
(Andanda 2008). The ethical use of biologi-
cal material collected in developing countries 
for use in economically developed countries 
is more complex (Upshur et al. 2007). Ethics 
review boards need to satisfy themselves that 
appropriate consent was obtained from the 
research subjects, using the procedure deemed 
appropriate by the local community and local 
ethical review board (Upshur et al. 2007). 
This may involve viewing in detail the trans-
lations of information sheets or informed 
consent documents and/or letters of approval 
from the relevant local authorities.
Research into housing-related health 
hazards and pesticide exposure in children. 
Although the primary purpose of housing is to 
provide a safe haven for normal living, there 
is an increasing recognition of the hazards 
that may exist in the indoor environment. A 
healthy and safe physical and psychosocial 
home environment is essential for the normal 
development of children, especially during 
the preschool years. Poor-quality housing and 
hazards found within the house can affect 
children’s health. In developing countries, the 
major hazards may include poor construction 
related to lack of high-quality building mate-
rials and skills; poor location on contaminated 
or disaster-prone sites; lack of basic services 
such as clean water, sanitation, and adequate 
waste disposal facilities; chronic infestation 
with rodents and other disease vectors; the 
use of biomass or solid fuel for cooking or 
heating; and overcrowding. In industrialized 
countries where the provision of basic services 
is likely to be adequate, hazards may include 
poor housing design or use of unhealthy 
building materials; poor heating or ventilation 
systems encouraging high loads of bio  aerosols 
and triggering or inducing chronic diseases 
such as asthma; and exposure to radon or 
electro  magnetic radiation (Pronczuk and 
Surdu 2008). Ethics of biomarker research in children
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Along with the increasing recognition of 
the health hazards associated with housing has 
come an increase in research into the health 
effects of housing environments. Two rela-
tively recent and well-publicized controversial 
events—namely, CHEERS and the 2001 
case of Grimes v. Kennedy Krieger Institute 
[see Supplemental Material (doi:10.1289/
ehp.0800480.S1)]—have highlighted ethical 
concerns with this type of research involv-
ing children. Debate has continued, especially 
in the area of research involving exposure of 
children to pesticides (Needleman et al. 2005; 
Resnik and Portier 2005), with Resnik and 
Portier contending that the benefits of inten-
tionally exposing humans to pesticides out-
weigh the risks of doing so. (They deliberately 
avoided the issue of testing in research involv-
ing exposure of children.) This argument was 
not accepted by a group of prominent inves-
tigators, who argued that the increased sus-
ceptibility of children to pesticides precluded 
the extrapolation of adult data to the pediatric 
age range. They also pointed out that it would 
be extremely difficult to adequately power an 
exposure study to detect effects that would 
harm 1 child in 1,000 (Needleman et al. 
2005). In addition, the arguments advanced 
by Resnik and Portier (2005) do not address 
the issues of research involving children, as 
discussed above.
A U.S. National Academy of Sciences 
committee report, Ethical Considerations for 
Housing-Related Health Hazards Involving 
Children (Lo and O’Connell 2005), high-
lighted the ethical issues that are more com-
mon in housing-related research than in other 
biomedical research, including the following:
•	The research may intrude into the privacy of 
residents.
•	The research is generally community based 
and frequently involves community con-
cerns about issues related to local housing.
•	Housing hazard research is more likely 
to target low-income families who live in 
poor-quality housing; thus, children of low-
income families are specifically targeted.
•	Concerns are likely to remain about haz-
ards that persist after the research has been 
  completed.
•	Economic and educational disadvantage 
and limited literacy may place low-income 
parents at a disadvantage in the informed 
  consent process.
•	Financial or other material incentives may 
present undue influences for parents in the 
decision to allow their children to participate 
in such research projects.
Readers interested in these issues are invited 
to consider the two case reports incorporated 
in the Supplemental Material (doi:10.1289/
ehp.0800480.S1).
The National Children’s Study. After many 
years of planning and preliminary studies, 
the U.S. National Children’s Study has been 
launched (National Children’s Study 2009). 
This study aims to include 100,000 children 
(with their families) from birth (or earlier) 
through 21 years of age and will include “a 
thorough history of exposures, biological sam-
ples, and health outcomes will be obtained 
from pregnancy onwards, allowing for com-
prehensive statistically powerful analyses of the 
link between a wide range of exposures and 
genetic factors with child health and develop-
ment” (National Children’s Study 2009). 
Much preparation has gone into the study, 
including a through assessment of the require-
ments for biological monitoring at different 
life stages (Barr et al. 2005), the methodologic 
and logistic issues involved in conducting lon-
gitudinal birth cohort studies (Eskanazi et al. 
2005), and the burden imposed on the family 
(Wagener 2003). This thorough preparation 
gives considerable comfort that this massive 
study will be conducted with due considera-
tion of the ethical issues in research involving 
biobanks and biomarkers in children.
Summary
Biomarker research in children poses some 
particular ethical problems, especially with 
regard to obtaining appropriate consent and 
deciding what information results can be fed 
back to the study participants and the com-
munity. Developing appropriate strategies 
for understanding and managing community 
expectations is important in all research, but 
especially for biomarker research involving 
children. An additional challenge is presented 
when this research is undertaken in countries 
where values, customs, and ethical guidelines 
are different from those countries where stud-
ies have been ongoing for several decades and 
a large body of experience has been collected. 
None of these challenges are insurmountable. 
Pediatric biomarker research is necessary for 
advancing child health.
RefeRences
Andanda PA. 2008. Human-tissue-related inventions: owner-
ship and intellectual property rights in international col-
laborative research in developing countries. J Med Ethics 
34(3):171–179.
Angell M. 1997. The ethics of clinical research in the Third 
World [Comment]. New Engl J Med 337(12):847–849.
[Anonymous.] 2007. Developing genetics for developing coun-
tries [Editorial]. Nat Genet 39(11):1287.
Barr DB, Wang RY, Needham LL. 2005. Biological monitoring 
of exposure to environmental chemicals throughout life 
stages: requirements and issues for consideration for 
the National Children’s Study. Environ Health Perspect 
113:1083–1091.
Beauchamp T, Childress J. 2005. Principles of Biomedical 
Ethics. New York:Oxford University Press.
Beecher HK. 1966. Ethics and clinical research. N Engl J Med 
274(24):1354–1360.
Canadian Institutes for Health Research. 2007. CIHR Guidelines 
for Health Research Involving Aboriginal People. Ottawa, 
Ontario, Canada:Canadian Institutes for Health Research.
Caulfield J, Brown R, Meslin M. 2007. Challenging a well 
established consent norm? One time consent for biobank 
research. J Int Biotechnol Law 4(2):69–74.
CHAMACOS. 2009. Center for the Health Assessment of 
Mothers and Children of Salinas (CHAMACOS). Available: 
http://ehs.sph.berkeley.edu/chamacos/  [accessed 
10 December 2008].
Cooke MS, Singh R, Hall GK, Mistry V, Duarte TL, Farmer PB, 
et al. 2006. Evaluation of enzyme-linked immunosorbent 
assay and liquid chromatography-tandem mass spectrom-
etry methodology for the analysis of 8-oxo-7,8-dihydro-2’-
deoxyguanosine in saliva and urine. Free Radic Biol Med 
41(12):1829–1836.
Council for International Organizations of Medical Sciences 
(CIOMS). 1993. International Ethical Guidelines for Biomedical 
Research Involving Human Subjects. Geneva:Council for 
International Organizations of Medical Sciences.
De Lourdes Levy M, Larcher V, Kurz R, Ethics Working Group of the 
Confederation of European Specialists in Paediatrics. 2003. 
Informed consent/assent in children. Statement of the Ethics 
Working Group of the Confederation of European Specialists 
in Paediatrics (CESP). Eur J Pediatr 162(9):629–633.
Department of Health and Human Services. 2005. Public 
Welfare: Code of Federal Regulations: Protection of 
Human Participants. 45CFR46. Available: http://www.hhs.
gov/ohrp/humansubjects/guidance/45cfr46.htm [accessed 
22 June 2009].
Dixon-Woods M, Young B, Ross E. 2006. Researching chronic 
childhood illness: the example of childhood cancer 
[Comment]. Chronic Illn 2(3):165–177.
Duncan RE. 2004. Predictive genetic testing in young people: when 
is it appropriate? J Paediatr Child Health 40(11):593–595.
Emanuel E, Weijer C. 2005. Protecting communities in research: 
from a new principle to rational protections. In: Belmont 
Revisited: Ethical Prinicples for Research with Human 
Subjects (Childress J, Meslin E, Shapiro H, eds). Washington. 
DC:Georgetown University Press, 165–183.
Eskenazi B, Gladstone E, Berkowitz G, Drew C, Faustman E, 
Holland N, et al. 2005. Methodological and logistic issues 
in conducting longitudinal birth cohort studies: lessons 
learned from the Centers for Children’s Environmental 
Health and Disease Prevention Research. Environ Health 
Perspect 113:1419–1429.
Evans BJ, Meslin EM. 2006. Encouraging translational research 
through harmonization of FDA and common rule informed 
consent requirements for research with banked speci-
mens. J Leg Med 27(2):119–166.
FDA (Food and Drug Administration). 2008. 21 CFR 50: Protection 
of Human Subjects and 21 CFR 56: Institutional Review 
Boards. Revised 2008. Available: http://www.accessdata.fda.
gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm. [accessed 
22 June 2009].
Gauderman WJ, Avol E, Gilliland F, Vora H, Thomas D, Berhane 
K, et al. 2004. The effect of air pollution on lung development 
from 10 to 18 years of age. N Engl J Med 351(11):1057–1067.
Genetic Information Nondiscrimination Act (GINA) of 2008. 2008. 
Available: http://www.gpo.gov/fdsys/pkg/PLAW-110publ233/
content-detail.html [accessed 22 June 2009]. 
Harwood DT, Kettle AJ, Winterbourn CC. 2006. Production of 
glutathione sulfonamide and dehydroglutathione from GSH 
by myeloperoxidase-derived oxidants and detection using 
a novel LC-MS/MS method. Biochem J 399(1):161–168.
Helft PR, Champion VL, Eckles R, Johnson CS, Meslin EM. 2007. 
Cancer patients’ attitudes toward future research uses of 
stored human biological materials. J Empir Res Hum Res 
Ethics 2(3):15–22.
Holdren J, Tao S, Carpenter DO. 2008. Environment and health 
in the twenty-first century: challenges and solutions. Ann 
NY Acad Sci 1140:1–21.
Holland N, Furlong C, Bastaki M, Richter R, Bradman A, Huen K, 
et al. 2006. Paraoxonase polymorphisms, haplotypes, and 
enzyme activity in Latino mothers and newborns. Environ 
Health Perspect 114:985–991.
Lo B, O’Connell ME, eds. 2005. Ethical Considerations for 
Research on Housing-Related Health Hazards Involving 
Children. Washington, DC:National Academies Press. 
Malkin D. 2004. Predictive genetic testing for childhood cancer: 
taking the road less traveled by [Comment]. J Pediatr 
Hematol Oncol 26(9):546–548.
McCormick R. 1976. Experimentation in children: sharing in 
sociality. Hastings Cent Rep 6(6):41–46.
Meslin E. 2009. Achieving global justice in health through 
global research ethics: supplementing Macklin’s “top-
down” approach with one from the “ground up.” In: Global 
Bioethics: Issues of Conscience for the Twenty-First Century 
(Green RM, Donovan A, Jauss SA, eds). New York:Oxford 
University Press.Sly et al.
1190  v o l u m e  117 | n u m b e r 8 | August 2009  •  Environmental Health Perspectives
Meslin E, Johnson S. 2008. National bioethics commissions and 
research ethics. In: The Oxford Textbook of Clinical Research 
Ethics (Emanuel E, Crouch R, Grady C, Lie R, Miller F, Wendler 
D, eds). New York:Oxford University Press, 187–197.
Mucha AP, Hryhorczuk D, Serdyuk A, Nakonechny J, Zvinchuk A, 
Erdal S, et al. 2006. Urinary 1-hydroxypyrene as a biomarker 
of PAH exposure in 3-year-old Ukrainian children. Environ 
Health Perspect 114:603–609.
National Children’s Study. 2009. National Children’s Study 
Home Page. Available: http://www.nationalchildrensstudy.
gov/ [accessed 10 December 2008].
National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research. 1975. Research on 
the Fetus. Available: http://www.bioethics.gov/reports/past_
commissions/research_fetus.pdf [accessed 22 June 2009]. 
National Commission for the Protection of Human Subjects 
of Biomedical and Behavioral Research. 1977. Research 
Involving Children. Available: http://www.bioethics.gov/
reports/past_commissions/Research_involving_children.
pdf [accessed 22 June 2009].
National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research. 1979. The Belmont 
Report: Ethical Principles and Guidelines for the Protection of 
Human Subjects of Research. Washington DC:Department of 
Health, Education, and Welfare.  Available: http://www.hhs.
gov/ohrp/humansubjects/guidance/belmont.htm [accessed 
10 December 2008].
National Health and Medical Research Council Australia. 
2007. National Statement on Ethical Conduct in Human 
Research. Available: http://www.nhmrc.gov.au/publications/ 
ethics/2007_humans/contents.htm [accessed 22 June 2009].
Needham LL, Sexton K. 2000. Assessing children’s exposure 
to hazardous environmental chemicals: an overview of 
selected research challenges and complexities. J Expo 
Anal Environ Epidemiol 10(6 pt 2):611–629.
Needleman HL, Reigart JR, Landrigan P, Sass J, Bearer C. 2005. 
Benefits and risk of pesticide testing on humans. Environ 
Health Perspect 113:A804–A805. 
Neidich AB, Joseph JW, Ober C, Ross LF. 2008. Empirical data 
about women’s attitudes towards a hypothetical pediatric 
biobank. Am J Med Genet A 146(3):297–304.
NIH (National Institutes of Health). 1998. NIH Policy and 
Guidelines on the Inclusion of Children as Participants 
in Research Involving Human Subjects. Available: http://
www.nhmrc.gov.au/publications/ethics/2007_humans/
contents.htm  [accessed 22 June 2009].
Page A. 2004. Ethical issues in international biomedical 
research: an overview. J Health Law 37(4):629–665.
Pronczuk J, Surdu S. 2008. Children’s environmental health in 
the twenty-first century. Ann NY Acad Sci 1140:143–154.
Quaid KA, Jessup NM, Meslin EM. 2004. Disclosure of genetic 
information obtained through research. Genet Test 
8(3):347–355.
Ramsey P. 1976. The enforcement of morals: nontherapeutic 
research on children: a reply to McCormick. Hastings Cent 
Rep 6(4):21–30. 
Resnik DB, Portier C. 2005. Pesticide testing on human sub-
jects: weighing benefits and risks. Environ Health Perspect 
113:813–817.
Romieu  I,  Barraza-Villarreal  A,  Escamilla-Nunez  C, 
Almstrand AC, Diaz-Sanchez D, Sly PD, et al. 2008. Exhaled 
breath malondialdehyde as a marker of effect of expo-
sure to air pollution in children with asthma. J Allergy Clin 
Immunol 121(4):903–909; e906.
Romieu I, Ramirez-Aguilar M, Sienra-Monge J, Moreno-
Marcias H, Estela del Rio-Navarro B, David G. 2006. 
GSTM1 and GSTP1 and respiratory health in asthmatic 
children exposed to ozone. Eur Respir J 28:953–959.
Romieu I, Samet JM, Smith KR, Bruce N. 2002. Outdoor air pol-
lution and acute respiratory infections among children in 
developing countries. J Occup Environ Med 44(7):640–649.
Schulte PA, Hunter D, Rothman N. 1997. Ethical and social issues 
in the use of biomarkers in epidemiological research. IARC 
Sci Pub 142:313–318.
Sewankambo N, Ijsselmuiden C. 2008. Responsive research in 
developing countries [Comment]. Lancet 372(9632):11–13.
Shaffer DN, Yebei VN, Ballidawa JB, Sidle JE, Greene JY, 
Meslin EM, et al. 2006. Equitable treatment for HIV/AIDS 
clinical trial participants: a focus group study of patients, 
clinician researchers, and administrators in western 
Kenya. J Med Ethics 32(1):55–60.
Shapiro HT, Meslin EM. 2001. Ethical issues in the design and 
conduct of clinical trials in developing countries. N Engl J 
Med 345(2):139–142.
Sharp RR, Zigas PH. 2002. Ethical and legal considerations in bio-
logical marker research. Boca Raton, FL:CRC Press, 17–25.
Sidle JE, Were E, Wools-Kaloustian K, Chuani C, Salmon K, 
Tierney WM, et al. 2006. A needs assessment to build 
international research ethics capacity. J Empir Res Hum 
Res Ethics 1(2):23–38.
Sly PD, Flack F. 2008. Susceptibility of children to environ  mental 
pollutants. Ann NY Acad Sci 1140:163–183.
Stick SM, Burton PR, Gurrin L, Sly PD, LeSouef PN. 1996. Effects 
of maternal smoking during pregnancy and a family history 
of asthma on respiratory function in newborn infants. 
Lancet 348(9034):1060–1064.
Thiessen C, Ssekubugu R, Wagman J, Kiddugavu M, Wawer MJ, 
Emanuel E, et al. 2007. Personal and community benefits 
and harms of research: views from Rakai, Uganda. AIDS 
21(18):2493–2501.
Torres-Dosal A, Perez-Maldonado IN, Jasso-Pineda Y, Martinez 
Salinas RI, Alegria-Torres JA, Diaz-Barriga F. 2008. Indoor 
air pollution in a Mexican indigenous community: evaluation 
of risk reduction program using biomarkers of exposure and 
effect. Sci Total Environ 390:362–368.
Upshur REG, Lavery JV, Tindana PO. 2007. Taking tissue seri-
ously means taking communities seriously. BMC Med 
Ethics 8:11.
Vork KL, Broadwin RL, Blaisdell RJ. 2007. Developing asthma in 
childhood from exposure to secondhand tobacco smoke: 
insights from a meta-regression. Environ Health Perspect 
115:1394–1400.
Wagener DK. 2003. Final Report: National Children’s Study 
(NCS) Estimating Subject Burden for Potential NCS 
Measurements. U.S. Environmental Protection Agency, 
Washington, DC, EPA/600/R-05/010. Available: http://www.
nationalchildrensstudy.gov/research/methodspilot/Pages/
Final-Report-National-Children-s-Study-NCS-Estimating-
Subject-Burden-for-Potential-NCS-Measurements.pdf 
[accessed 22 June 2009].
Widdows H. 2007. Is global ethics moral neo-colonialism? 
An investigation of the issue in the context of bioethics. 
Bioethics 21(6):305–315. 
Wolf L, Lo B. 2004. Untapped potential: IRB guidance for the 
ethical research use of biological materials IRB 26(4):1–8.
WHO. 2001. Environmental Health Criteria 222. Biomarkers in 
Risk Assessment: Validity and Validation. Geneva:World 
Health Organization.
WHO. 2006. Environmental Health Criteria 237. Principles 
for Evaluating the Health Risks in Children Associated 
with Exposure to Chemicals. Geneva:World Health 
Organization.
World Medical Association. 2008. Declaration of Helsinki: 
Ethical Principles for Medical Research Involving Human 
Subjects. Available: http://www.wma.net/e/policy/b3.htm 
[accessed 22 June 2009].